Advertising and pharmaceutical industry experts say an executive order Trump signed last week could threaten the business of both drugmakers and their media companies, which raked in an estimated $5billion in ad revenue from Big Pharma in 2024. The order instructs the Department of Health and Human Services to ensure “transparency and accuracy”.


